EMEA-000689-PIP01-09-M11
Key facts
Invented name |
|
Active substance |
exenatide
|
Therapeutic area |
Endocrinology-Gynaecology-Fertility-Metabolism
|
Decision number |
P/0064/2021
|
PIP number |
EMEA-000689-PIP01-09-M11
|
Pharmaceutical form(s) |
|
Condition(s) / indication(s) |
Treatment of type II diabetes mellitus
|
Route(s) of administration |
Subcutaneous use
|
Contact for public enquiries |
AstraZeneca AB
E-mail: paediatrics@astrazeneca.com
Tel: +46 855327591 |
Decision type |
PM: decision on the application for modification of an agreed PIP
|
Compliance procedure number |
EMEA-C-000689-PIP01-09-M11
|
Compliance opinion date |
21/05/2021
|
Compliance outcome |
positive
|